Horizon Therapeutics Publ... (HZNP)
Horizon Therapeutics Public Statistics
Share Statistics
Horizon Therapeutics Public has 228.74M shares outstanding. The number of shares has increased by -0.39% in one year.
Shares Outstanding | 228.74M |
Shares Change (YoY) | -0.39% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 211.06M |
Failed to Deliver (FTD) Shares | - |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
Short Interest | - |
Short % of Shares Out | null% |
Short % of Float | null% |
Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is null. Horizon Therapeutics Public's PEG ratio is undefined.
PE Ratio | undefined |
Forward PE | n/a |
PS Ratio | 7.18 |
Forward PS | null |
PB Ratio | 5.14 |
P/FCF Ratio | undefined |
PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Horizon Therapeutics Public.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85, with a Debt / Equity ratio of undefined.
Current Ratio | 3.85 |
Quick Ratio | 3.67 |
Debt / Equity | undefined |
Debt / EBITDA | - |
Debt / FCF | - |
Interest Coverage | undefined |
Financial Efficiency
Return on Equity is 0.1% and Return on Invested Capital is 8%.
Return on Equity | 0.1% |
Return on Assets | 0.06% |
Return on Invested Capital | 8% |
Revenue Per Employee | $1.66M |
Profits Per Employee | $238.12K |
Employee Count | 2,190 |
Asset Turnover | 0.4 |
Inventory Turnover | 5.43 |
Taxes
Income Tax | 5.45M |
Effective Tax Rate | 0.01% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.01, so Horizon Therapeutics Public's price volatility has been higher than the market average.
Beta | 1.01 |
52-Week Price Change | null% |
50-Day Moving Average | 110.78 |
200-Day Moving Average | 108.29 |
Relative Strength Index (RSI) | 83.96 |
Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Horizon Therapeutics Public had revenue of 3.63B and earned 521.48M in profits. Earnings per share was 2.28.
Revenue | 3.63B |
Gross Profit | 2.71B |
Operating Income | 617.41M |
Net Income | 521.48M |
EBITDA | 1.11B |
EBIT | 617.41M |
Earnings Per Share (EPS) | 2.28 |
Balance Sheet
The company has 2.35B in cash and 2.56B in debt, giving a net cash position of -210M.
Cash & Cash Equivalents | 2.35B |
Total Debt | 2.56B |
Net Cash | -210M |
Retained Earnings | 590.01M |
Total Assets | 9.3B |
Working Capital | 3B |
Cash Flow
In the last 12 months, operating cash flow was 1.26B and capital expenditures -126.28M, giving a free cash flow of 1.13B.
Operating Cash Flow | 1.26B |
Capital Expenditures | -126.28M |
Free Cash Flow | 1.13B |
FCF Per Share | 4.94 |
Margins
Gross margin is 74.64%, with operating and profit margins of 17.01% and 14.37%.
Gross Margin | 74.64% |
Operating Margin | 17.01% |
Pretax Margin | 14.52% |
Profit Margin | 14.37% |
EBITDA Margin | 30.71% |
EBIT Margin | 17.01% |
FCF Margin | 31.18% |
Dividends & Yields
HZNP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for HZNP.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 5.09 |
Piotroski F-Score | 8 |